These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15566329)

  • 1. Dalbavancin: an investigational glycopeptide.
    Guay DR
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):845-52. PubMed ID: 15566329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
    Kim A; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
    Dorr MB; Jabes D; Cavaleri M; Dowell J; Mosconi G; Malabarba A; White RJ; Henkel TJ
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii25-30. PubMed ID: 15750034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.
    Leuthner KD; Yuen A; Mao Y; Rahbar A
    Expert Rev Anti Infect Ther; 2015 Feb; 13(2):149-59. PubMed ID: 25578881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycopeptide antibiotics: back to the future.
    Butler MS; Hansford KA; Blaskovich MA; Halai R; Cooper MA
    J Antibiot (Tokyo); 2014 Sep; 67(9):631-44. PubMed ID: 25118105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
    Nailor MD; Sobel JD
    Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
    Jones RN; Fritsche TR; Sader HS; Goldstein BP
    J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
    Streit JM; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open study of teicoplanin in the treatment of gram-positive infections.
    Nathwani D; Reid TM; Gould IM; Golder D; Smith CC; Douglas JG
    J Chemother; 1991 Oct; 3(5):315-20. PubMed ID: 1839742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalbavancin (Biosearch Italia/Versicor).
    Steiert M; Schmitz FJ
    Curr Opin Investig Drugs; 2002 Feb; 3(2):229-33. PubMed ID: 12020051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.